Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02656472 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT02656472 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 22 participants.
The verdict
NCT02656472, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to compare anti-inflammatory effects of two anti-fibrinolytic drugs (Tranexamic acid versus Epsilon-aminocaproic acid) in pediatric patients undergoing pediatric cardiac surgery.
Interventions
- DRUG Tranexamic acid
- DRUG Epsilon Aminocaproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02656472
The ClinicalTrials.gov registry entry for NCT02656472 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tranexamic acid is the first listed.
NCT02656472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02656472 about?
NCT02656472 is a clinical study titled "A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery". The purpose of this study is to compare anti-inflammatory effects of two anti-fibrinolytic drugs (Tranexamic acid versus Epsilon-aminocaproic acid) in pediatric patients undergoing pediatric cardiac surgery.
What is the current status of trial NCT02656472?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2016-02. Estimated completion is 2017-04.
What interventions are being tested in trial NCT02656472?
The interventions under investigation include: Tranexamic acid (DRUG), Epsilon Aminocaproic Acid (DRUG).
Who is sponsoring clinical trial NCT02656472?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.